published meta-analysis   sensitivity analysis   studies

adjuvant therapies in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRAPID (Sholzberg), 2021 0.22 [0.07; 0.67] 0.22[0.07; 0.67]RAPID (Sholzberg), 202110%465NAnot evaluable death or transfer to ICUdetailed resultsRAPID (Sholzberg), 2021 0.70 [0.44; 1.12] 0.70[0.44; 1.12]RAPID (Sholzberg), 202110%465NAnot evaluable deathsdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20] RAPID (Sholzberg), 2021 0.22 [0.07; 0.67] 0.49[0.13; 1.87]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, RAPID (Sholzberg), 2021282%2,691moderatenot evaluable clinical deteriorationdetailed resultsRAPID (Sholzberg), 2021 0.69 [0.43; 1.10] 0.69[0.43; 1.10]RAPID (Sholzberg), 202110%465NAnot evaluable clinical improvement (28-day)detailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57] 1.27[1.03; 1.57]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,219NAnot evaluable death or ventilationdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07] RAPID (Sholzberg), 2021 0.59 [0.34; 1.02] 0.76[0.58; 1.00]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, RAPID (Sholzberg), 2021211%2,696moderatenot evaluable mechanical ventilationdetailed resultsRAPID (Sholzberg), 2021 0.70 [0.32; 1.54] 0.70[0.32; 1.54]RAPID (Sholzberg), 202110%465NAnot evaluable ICU admissiondetailed resultsRAPID (Sholzberg), 2021 0.79 [0.48; 1.30] 0.79[0.48; 1.30]RAPID (Sholzberg), 202110%465NAnot evaluable Major bleedingdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67] 1.80[0.88; 3.67]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,227NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-28 12:34 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960 - roots T: 290